Dietzsch, Stefan, Placzek, Felix, Pietschmann, Klaus, von Bueren, Andre O., Matuschek, Christiane, Glueck, Albrecht, Guckenberger, Matthias, Budach, Volker, Welzel, Jutta, Poettgen, Christoph, Schmidberger, Heinz, Heinzelmann, Frank, Paulsen, Frank, Escudero, Montserrat Pazos, Schwarz, Rudolf, Hornung, Dagmar, Martini, Carmen, Grosu, Anca Ligia, Stueben, Georg, ablonska, Karolina J., Dunst, Juergen, Stranzl-Lawatsch, Heidi, Dieckmann, Karin, Timmermann, Beate, Pietsch, Torsten, Warmuth-Metz, Monika, Bison, Brigitte, Kwiecien, Robert, Benesch, Martin, Gerber, Nicolas U., Grotzer, Michael A., Pfister, Stefan M., Clifford, Steven C., von Hoff, Katja, Klagges, Sabine, Rutkowski, Stefan, Kortmann, Rolf-Dieter and Mynarek, Martin (2020). Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma - A Report From the HIT 2000 Trial. Adv. Radiat. Oncol., 5 (6). S. 1158 - 1170. SAN DIEGO: ELSEVIER INC. ISSN 2452-1094

Full text not available from this repository.

Abstract

Purpose: We aimed to compare treatment results in and outside of a randomized trial and to confirm factors influencing outcome in a large retrospective cohort of nonmetastatic medulloblastoma treated in Austria, Switzerland and Germany. Methods and Materials: Patients with nonmetastatic medulloblastoma (n = 382) aged 4 to 21 years and primary neurosurgical resection between 2001 and 2011 were assessed. Between 2001 and 2006, 176 of these patients (46.1%) were included in the randomized HIT SIOP PNET 4 trial. From 2001 to 2011 an additional 206 patients were registered to the HIT 2000 study center and underwent the identical central review program. Three different radiation therapy protocols were applied. Genetically defined tumor entity (former molecular subgroup) was available for 157 patients. Results: Median follow-up time was 7.3 (range, 0.09-13.86) years. There was no difference between HIT SIOP PNET 4 trial patients and observational patients outside the randomized trial, with 7 years progression-free survival rates (PFS) of 79.5% 3.1% versus 78.7% 3.1% (P = .62). On univariate analysis, the time interval between surgery and irradiation ( 48 days vs 49 days) showed a strong trend to affect PFS (80.4% +/- 2.2% vs 64.6% +/- 9.1%; P = .052). Furthermore, histologically and genetically defined tumor entities and the extent of postoperative residual tumor influenced PFS. On multivariate analyses, a genetically defined tumor entity wingless-related integration site-activated vs non-wingless-related integration site/non-SHH, group 3 hazard ratio, 5.49; P = .014) and time interval between surgery and irradiation (hazard ratio, 2.2; P = .018) were confirmed as independent risk factors. Conclusions: Using a centralized review program and risk-stratified therapy for all patients registered to the study center, outcome was identical for patients with nonmetastatic medulloblastoma treated on and off the randomized HIT SIOP PNET 4 trial. The prognostic values of prolonged time to RT and genetically defined tumor entity were confirmed. (C) 2020 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Dietzsch, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Placzek, FelixUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pietschmann, KlausUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Bueren, Andre O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Matuschek, ChristianeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Glueck, AlbrechtUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Guckenberger, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Budach, VolkerUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Welzel, JuttaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Poettgen, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schmidberger, HeinzUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Heinzelmann, FrankUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Paulsen, FrankUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Escudero, Montserrat PazosUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schwarz, RudolfUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hornung, DagmarUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Martini, CarmenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grosu, Anca LigiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stueben, GeorgUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
ablonska, Karolina J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dunst, JuergenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stranzl-Lawatsch, HeidiUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dieckmann, KarinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Timmermann, BeateUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pietsch, TorstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Warmuth-Metz, MonikaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bison, BrigitteUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kwiecien, RobertUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Benesch, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gerber, Nicolas U.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Grotzer, Michael A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pfister, Stefan M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Clifford, Steven C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
von Hoff, KatjaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klagges, SabineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rutkowski, StefanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kortmann, Rolf-DieterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mynarek, MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-312596
DOI: 10.1016/j.adro.2020.09.018
Journal or Publication Title: Adv. Radiat. Oncol.
Volume: 5
Number: 6
Page Range: S. 1158 - 1170
Date: 2020
Publisher: ELSEVIER INC
Place of Publication: SAN DIEGO
ISSN: 2452-1094
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHILDHOOD MEDULLOBLASTOMA; RISK MEDULLOBLASTOMA; MOLECULAR SUBGROUPS; RADIATION-THERAPY; PHASE-III; RADIOTHERAPY; CHEMOTHERAPY; CLASSIFICATION; CHILDREN; SURVIVALMultiple languages
Oncology; Radiology, Nuclear Medicine & Medical ImagingMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/31259

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item